Gyula Szabó
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gyula Szabó has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
Gyula Telegdy
Department of Pathophysiology, Faculty of Medicine, University of Szeged, Hungary
37 shared publications- Zoltán Sarnyai
Laboratory of Psychiatric Neurosciences, Australian Institute of Tropical Health and Medicine, James Cook University, Australia
18 shared publications Gábor L. Kovács
16 shared publicationsKrisztina Csabafi
Department of Pathophysiology, Faculty of Medicine, University of Szeged, Hungary
11 shared publicationsPaula L. Hoffman
Department of Pharmacology, University of Colorado Health Sciences Center, 4200E 9th Ave, Box C236, Denver, CO 80262, USA
8 shared publications- Roberta Dochnal
Department of Pathophysiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
8 shared publications
Latest Publications
- 1 February 2018
- Published by Elsevier in Brain Research
- Vol. 1680, 62-68
Anxiolytic- and antidepressant-like actions of Urocortin 2 and its fragments in mice
- 1 February 2018
- Published by Elsevier in Brain Research
- Vol. 1680, 62-68
Anxiolytic- and antidepressant-like actions of Urocortin 2 and its fragments in mice
- 1 November 2017
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 95 (11) , 1319-1326
Effects of kisspeptin on diabetic rat platelets
Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.
- 1 November 2017
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 95 (11) , 1319-1326
Effects of kisspeptin on diabetic rat platelets
Hyperglycemia, hyperlipidemia, and free radicals result in platelet activation and atherogenesis. Kisspeptin (KP) is able to regulate metabolism, hemostasis, and the development of atherosclerosis. We examined whether platelet aggregation of streptozotocin-induced diabetic rats depends on the inducer type and if KP-13 and RF-9 (a kisspeptin receptor modifier) can influence platelet function. We measured the speed and the maximum of aggregation, along with the area under the curve. Serum glucose and calcium levels and urine formation of diabetic animals increased, while the body mass and platelet count decreased. Collagen was the most effective inducer of platelet aggregation. The aggregability of nondiabetic platelets was elevated in the presence of 5 × 10−8 mol/L KP-13. This effect was less expressed in diabetic animals. The effectivity of RF-9 was stronger than that of KP-13 in nondiabetic platelets, however it was ineffective in diabetic animals. RF-9 pre-treatment did not change the effects of 5 × 10−8 mol/L KP-13 in either animal group. The in vivo activation of diabetic platelets, which may be due to elevated serum calcium, induces thrombocytopenia and may lead to reduced in vitro aggregability. We could not demonstrate the antagonistic effect of RF-9 against KP-13 in isolated platelets.
- 1 December 2016
- Published by Elsevier in Brain Research
- Vol. 1652, 21-29
Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice
- 1 December 2016
- Published by Elsevier in Brain Research
- Vol. 1652, 21-29
Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice
- 1 November 2015
- Published by Elsevier in Neurochemistry International
- Vol. 90, 67-71
The effects of CRF and urocortins on the hippocampal glutamate release
- 1 November 2015
- Published by Elsevier in Neurochemistry International
- Vol. 90, 67-71
The effects of CRF and urocortins on the hippocampal glutamate release
- 1 October 2015
- Published by Elsevier in Behavioural Brain Research
- Vol. 293, 41-45
The effect of obestatin on anxiety-like behaviour in mice
- 1 October 2015
- Published by Elsevier in Behavioural Brain Research
- Vol. 293, 41-45
The effect of obestatin on anxiety-like behaviour in mice
- 1 September 2015
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 93 (9) , 787-791
The effect of kisspeptin on the regulation of vascular tone
Kisspeptin has been implicated in cardiovascular control. Eicosanoids play a crucial role in the activation of platelets and the regulation of vascular tone. In the present study, we investigated the effect of kisspeptins on eicosanoid synthesis in platelets and aorta in vitro. Platelets and aorta were isolated from Wistar–Kyoto rats. After preincubation with different doses of kisspeptin, samples were incubated with [1-14C]arachidonic acid (0.172 pmol/mL) in tissue culture Medium 199. The amount of labeled eicosanoids was measured with liquid scintillation, after separation with overpressure thin-layer chromatography. Kisspeptin-13 stimulated the thromboxane synthesis. The dose–response curve was bell-shaped and the most effective concentration was 2.5 × 10−8 mol/L, inducing a 27% increase. Lipoxygenase products of platelets displayed a dose-dependent elevation up to the dose of 5 × 10−8 mol/L. In the aorta, kisspeptin-13 induced a marked elevation in the production of 6-keto-prostaglandin F1α, the stable metabolite of prostacyclin, and lipoxygenase products. Different effects of kisspeptin on cyclooxygenase and lipoxygenase products indicate that beyond intracellular Ca2+ mobilization, other signaling pathways might also contribute to its actions. Our data suggest that kisspeptin, through the alteration of eicosanoid synthesis in platelets and aorta, may play a physiologic and (or) pathologic role in the regulation of vascular tone.
- 1 September 2015
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 93 (9) , 787-791
The effect of kisspeptin on the regulation of vascular tone
Kisspeptin has been implicated in cardiovascular control. Eicosanoids play a crucial role in the activation of platelets and the regulation of vascular tone. In the present study, we investigated the effect of kisspeptins on eicosanoid synthesis in platelets and aorta in vitro. Platelets and aorta were isolated from Wistar–Kyoto rats. After preincubation with different doses of kisspeptin, samples were incubated with [1-14C]arachidonic acid (0.172 pmol/mL) in tissue culture Medium 199. The amount of labeled eicosanoids was measured with liquid scintillation, after separation with overpressure thin-layer chromatography. Kisspeptin-13 stimulated the thromboxane synthesis. The dose–response curve was bell-shaped and the most effective concentration was 2.5 × 10−8 mol/L, inducing a 27% increase. Lipoxygenase products of platelets displayed a dose-dependent elevation up to the dose of 5 × 10−8 mol/L. In the aorta, kisspeptin-13 induced a marked elevation in the production of 6-keto-prostaglandin F1α, the stable metabolite of prostacyclin, and lipoxygenase products. Different effects of kisspeptin on cyclooxygenase and lipoxygenase products indicate that beyond intracellular Ca2+ mobilization, other signaling pathways might also contribute to its actions. Our data suggest that kisspeptin, through the alteration of eicosanoid synthesis in platelets and aorta, may play a physiologic and (or) pathologic role in the regulation of vascular tone.
- 1 February 2014
- Published by Elsevier in Neuropeptides
- Vol. 48 (1) , 15-20
The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis
- 1 February 2014
- Published by Elsevier in Neuropeptides
- Vol. 48 (1) , 15-20
The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis
- Open Access
- 24 November 2013
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-9
Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonists
Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several analogues have been synthesized to improve their binding and pharmacological profiles. We have shown previously that a new analogue,cis-1S,2R-aminocyclohexanecarboxylic acid2-endomorphin-2 (ACHC-EM2), had elevated mu-receptor affinity, selectivity, and proteolytic stability over the parent compound. In the present work, we have studied its antinociceptive effects and receptor regulatory processes. ACHC-EM2 displayed a somewhat higher (60%) acute antinociceptive response than the parent peptide, EM2 (45%), which peaked at 10 min afterintracerebroventricular (icv)administration in the rat tail-flick test. Analgesic tolerance developed to the antinociceptive effect of ACHC-EM2 upon its repeatedicvinjection that was complete by a 10-day treatment. This was accompanied by attenuated coupling of mu-sites to G-proteins in subcellular fractions of rat brain. Also, the density of mu-receptors was upregulated by about 40% in the light membrane fraction, with no detectable changes in surface binding. Distinct receptor regulatory processes were noted in subcellular fractions of rat brains made tolerant by the prototypic full mu-agonist peptide, DAMGO, and its chloromethyl ketone derivative, DAMCK. These results are discussed in light of the recently discovered phenomenon, that is, the “so-called biased agonism” or “functional selectivity”.
- 24 November 2013
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-9
Open AccessLigand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonists
Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several analogues have been synthesized to improve their binding and pharmacological profiles. We have shown previously that a new analogue,cis-1S,2R-aminocyclohexanecarboxylic acid2-endomorphin-2 (ACHC-EM2), had elevated mu-receptor affinity, selectivity, and proteolytic stability over the parent compound. In the present work, we have studied its antinociceptive effects and receptor regulatory processes. ACHC-EM2 displayed a somewhat higher (60%) acute antinociceptive response than the parent peptide, EM2 (45%), which peaked at 10 min afterintracerebroventricular (icv)administration in the rat tail-flick test. Analgesic tolerance developed to the antinociceptive effect of ACHC-EM2 upon its repeatedicvinjection that was complete by a 10-day treatment. This was accompanied by attenuated coupling of mu-sites to G-proteins in subcellular fractions of rat brain. Also, the density of mu-receptors was upregulated by about 40% in the light membrane fraction, with no detectable changes in surface binding. Distinct receptor regulatory processes were noted in subcellular fractions of rat brains made tolerant by the prototypic full mu-agonist peptide, DAMGO, and its chloromethyl ketone derivative, DAMCK. These results are discussed in light of the recently discovered phenomenon, that is, the “so-called biased agonism” or “functional selectivity”.